Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

QYuns, an Autoimmune/Allergic Disease Biotech, Files for Hong Kong IPO

publication date: Oct 6, 2023

Jiangsu QYuns Therapeutics filed for a Hong Kong IPO to underwrite development of its portfolio of clinical stage biologic antibody drugs for autoimmune and allergic diseases. The company has developed a pipeline of nine candidates using its rabbit-based discovery platform that it expects will be more affordable than the competition. QYuns says the platform offers a 50-fold increase in B cells for more screening, better affinity and greater diversity than mouse-based technology. However, QYuns’ first approved drug will probably be QX001S, a ustekinumab biosimilar aimed at psoriasis, rather than one of its novel candidates. QYuns has submitted a BLA for QX001S in China, the first for the indication. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital